YOLFTbeta
Puriblood Medical Co., Ltd.

Puriblood Medical Co., Ltd.

6847 · TWO · Healthcare / Diagnostics & Research

69.70TWD+1.70 (+2.50%)

Price History

Full chart

Market Stats

Previous Close68.00
Open69.70
Day Range69.70 – 69.70
52-Week Range47.75 – 93.70
Volume100
Market Cap1.28B
P/E (TTM)0.00
Forward P/E0.00
EPS-3.89
Dividend Yield0.00%
Beta0.14
50-Day Avg75.11
200-Day Avg71.79

About

Puriblood Medical Co., Ltd. engages in the research and development of blood purification-related medical devices in Taiwan and internationally. The company offers leukoreduction, cell separation, and P-Tex, an anti-fouling technology, which is composed by bio-inspired molecular formula. It is also involved in animal blood transfusion. Puriblood Medical Co., Ltd. was incorporated in 2015 and is based in Hsinchu City, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEODr. Yanwen Chen
  • Employees38
  • HeadquartersNo. 11, Industrial East 9th Rd., Hsinchu City, Taiwan, 300096, Taiwan
  • Websitehttps://www.puriblood.com

Leadership

  • Dr. Yanwen ChenChairman & President
  • Prof. Yung ChangFounder & Consultant
  • Xiaowen Jiang FangAccounting Supervisor

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue3.09M38.65M54.59M137.44M125.27M110.67M82.33M
Growth (%)-+1149.06%+41.25%+151.79%-8.86%-11.65%-25.61%
Cost of Revenue3.45M14.27M48.99M78.78M118.75M53.87M50.03M
Gross Profit-357.00K24.38M5.60M58.66M6.52M56.81M32.31M
Gross Margin-11.54%63.08%10.26%42.68%5.21%51.33%39.24%
Operating Expense21.04M27.67M40.99M51.43M56.93M59.55M65.74M
Operating Income-21.40M-3.30M-35.40M7.24M-50.40M-2.74M-33.44M
Operating Margin-691.56%-8.53%-64.84%5.27%-40.24%-2.48%-40.61%
EBITDA-15.75M3.46M-30.80M26.02M-44.02M4.15M-29.89M
EBITDA Margin-509.15%8.95%-56.42%18.93%-35.14%3.75%-36.30%
Net Income-20.55M-2.78M-38.02M16.53M-51.59M-5.37M-39.00M
Net Income Margin-664.29%-7.19%-69.66%12.03%-41.19%-4.85%-47.37%
R&D12.54M14.70M20.77M22.44M25.95M31.23M33.47M
R&D as % of Total Revenue405.40%38.03%38.04%16.32%20.72%28.21%40.65%
Interest Expense729.00K1.08M730.00K1.31M1.35M803.00K1.07M
Interest Expense % of Total Revenue23.56%2.79%1.34%0.96%1.08%0.73%1.30%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets85.47M196.11M265.60M320.50M265.51M259.15M236.68M
Total Liabilities58.85M51.94M49.11M87.47M84.35M83.75M96.47M
Total Equity26.62M144.17M216.50M233.03M181.16M175.40M140.21M
Cash1.67M99.84M131.87M99.50M117.48M86.61M60.43M
Total Debt40.68M33.86M30.48M56.61M51.64M51.84M-
Net Debt39.01M-65.97M-101.39M-42.89M-65.84M-34.77M-

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-15.54M-9.62M-43.68M-30.83M26.64M-29.68M-27.39M
Investing Cash Flow-5.40M-15.82M-24.35M-25.64M-3.25M-1.40M-
Financing Cash Flow14.63M112.05M100.06M24.10M-5.42M204.00K-
Capital Expenditure4.17M10.09M5.09M11.47M6.35M2.06M479.00K
Free Cash Flow-19.71M-19.71M-48.77M-42.30M20.30M-31.74M-27.87M
FCF to OCF126.85%204.85%111.65%137.21%76.18%106.95%101.75%

Key Statistics & Ratios

Market Cap1.28B
Enterprise Value1.22B
Trailing P/E0.00
Forward P/E0.00
Price / Sales15.89
Price / Book11.04
EPS-3.89
Book Value7.69
Revenue (TTM)80.54M
Gross Profit (TTM)17.88M
EBITDA-41.58M
Profit Margin-69.30%
Operating Margin-64.15%
Return on Equity-40.93%
Return on Assets-12.98%
Shares Outstanding17.23M
Shares Float6.42M
Beta0.14
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%